DVT prophylaxis in hospitalized and critically ill patients

DVT prophylaxis in hospitalized and critically ill patients 

Every hospitalized/critically ill patient should undergo a daily assessment of VTE risk AND bleeding risk. If VTE risk is significant and bleeding risk is acceptable → pharmacological prophylaxis, usually LMWH, is preferred. If pharmacological prophylaxis is contraindicated → intermittent pneumatic compression (IPC) should be used.

Why ICU patients are at high risk of DVT

The classical mechanism is Virchow’s triad:

VTE risk versus bleeding risk

• VTE risk HIGH + bleeding risk LOW → pharmacological prophylaxis
• VTE risk HIGH + bleeding risk HIGH → mechanical prophylaxis
• VTE risk LOW + bleeding risk HIGH → often no pharmacological prophylaxis

IMPROVE-BLEED score(including ICU)

Interpretation

Padua Prediction Score 

Padua score was developed for acutely ill medical inpatients, not specifically for ICU patients.

Interpretation

For surgical/trauma patients

And don’t mix these with PE/DVT diagnostic scoresThese are not prophylaxis scores:

contraindications/cautions include:

• Active bleeding
• platelets <50,000/µL
• significant coagulopathy(INR >1.5,aPTT >1.5× normal)

Other important situations

• Recent major surgery
• Recent neurosurgery
• Acute intracranial hemorrhage
• Unstable intracranial lesion
• Recent invasive procedure
• Severe uncontrolled hypertension in selected high-risk bleeding situations
• High-risk vascular lesion
• Held before Lumbar Puncture

Types of DVT prophylaxis

1. Pharmacological

• LMWH
• UFH
• occasionally fondaparinux in selected patients

2. Mechanical

• Intermittent pneumatic compression (IPC)
• Graduated compression stockings (GCS)

3. Combined

• Pharmacological + mechanical

But combined prophylaxis is not routinely required for every ICU patient. In sepsis and general ICU populations, routine addition of mechanical prophylaxis to pharmacological prophylaxis has not demonstrated sufficient benefit to recommend it universally. 

Pharmacological prophylaxis

LMWH

LMWH is generally preferred over UFH when there is no major contraindication.

Advantages

• More predictable pharmacokinetics
• Once-daily administration commonly possible
• Lower HIT risk
• LMWH is more effective and causes less bleeding

Enoxaparin

• CrCl ≥30 mL/min—40 mg SC once daily
• CrCl <30 mL/min—30 mg SC once daily

Low body weight:Female <45 kg,Male <57 kg

→ Standard prophylactic doses may result in increased exposure.

→ Consider bleeding risk carefully.

Enoxaparin 30 mg SC BD For orthopedics Surgical Prophylaxis

Trauma dosing is different

In many trauma protocols:Enoxaparin 40 mg SC BID

is used as an initial standard dose in many adult trauma patients because traditional 30 mg BID may provide inadequate prophylaxis in a substantial proportion of trauma patients. 

The Western Trauma Association algorithm describes:

• 40 mg BID for many adults 18–65 years, >50 kg and with CrCl >60 mL/min
• 30 mg BID for older patients, low body weight, or CrCl 30–60 mL/min

with dose adjustment according to patient characteristics and institutional protocols. 

• Prophylactic enoxaparin is contraindicated for GFR <20 ml/min.
• Therapeutic enoxaparin is contraindicated for GFR <30 ml/min.

Dalteparin 

• DOSE-5000U SC O.D

UFH(unfractionated heparin)

Prophylactic doses:UFH 5,000 units SC every TDS ,Low body weight or age >80 use B.D dosing 

Advantages of UFH

• Shorter half-life
• Less renal dependence
• Easier to stop before procedures
• Useful in severe renal dysfunction
• Reversible with protamine

Disadvantages

• More injections
• HIT risk
• Variable pharmacodynamic effect
• Less convenient than LMWH

Fondaparinux

Fondaparinux is a selective factor Xa inhibitor.

Dose-2.5 mg SC once daily( Note-same dose for NSTEMI patients with no plan for cardiac catheterization)

Advantages:

• once daily
• no HIT cross-reactivity in the same way as heparins so use in HIT (heparin-induced thrombocytopenia)

But important limitations:

• GFR <30 ml/min is an absolute contraindication
• It has no reversal.
• very long half-life at 17-21 hours.
• limited ICU-specific evidence

DOACs

• ASH recommends LMWH rather than DOACs for acutely ill hospitalized medical patients. Reasons:altered absorption,renal dysfunction,hepatic dysfunction,drug interactionsprocedures,enteral feeding issues,limited ICU-specific evidence
• Can be used in high risk Patient Who refused LMWH,UFH injections.

 Apixaban

Hip/knee replacement prophylaxis

Apixaban 2.5 mg PO BID

Usually started:

• 12–24 hours after surgery, depending on bleeding/hemostasis and the specific procedure.

Typical duration:

• Knee replacement: ~12 days
• Hip replacement: ~35 days

The duration is procedure-specific, not simply “until discharge.”

Rivaroxaban

Hip/knee replacement

Rivaroxaban 10 mg PO once daily

Typical duration:

• Knee replacement → approximately 12 days
• Hip replacement → approximately 35 days

Mechanical prophylaxis

Intermittent pneumatic compression(IPC)

IPC is generally the preferred mechanical method over GCS(Graduated compression stockings)when pharmacological prophylaxis cannot be given.

Mechanism:intermittent limb compression → increased venous flow → reduced venous stasis → potentially increased fibrinolytic activity.

Graduated compression stockings

GCS provide continuous graduated pressure:

highest at ankle → progressively lower proximally

They reduce venous pooling.

Potential problems with GCS:

• improper sizing
• skin injury
• pressure injury
• peripheral arterial disease
• impaired skin integrity
• inability to inspect skin adequately

Contraindications/cautions for mechanical prophylaxis

Be cautious with IPC/GCS in:

• severe peripheral arterial disease
• significant limb ischemia
• severe peripheral neuropathy
• major skin lesions
• burns
• severe edema with compromised skin
• acute limb ischemia
• existing DVT in certain circumstances
• limb trauma or recent vascular surgery

Do not put a compression device over an area where compression could cause injury.

IVC filter

Do NOT use an IVC filter routinely for primary prophylaxis.

An IVC filter does not prevent formation of DVT.

It is intended to prevent embolization to the pulmonary circulation in selected patients.

ASH guidelines recommend against prophylactic IVC filter placement in major surgery. 

Typical scenario where an IVC filter might be considered:

Acute proximal DVT/PE + absolute contraindication to anticoagulation

Mobilization

Early mobilization Whenever clinically feasible should be encouraged:

• passive ROM
• active ROM
• sitting
• standing
• ambulation
• physiotherapy

But:Mobilization does not automatically replace pharmacological prophylaxis in a high-risk immobilized ICU patient.

Duration of prophylaxis

The consensus recommends continuing prophylaxis until ICU discharge, although evidence for routine extension beyond hospitalization is limited. 

After ICU:Reassess:

• mobility
• ongoing illness
• cancer
• surgery
• previous VTE
• bleeding risk
• discharge destination

Do not automatically continue anticoagulant prophylaxis after discharge in every medical ICU patient.

ASH recommends against routine extended outpatient prophylaxis for most acutely ill medical patients. 

Extended prophylaxis

Extended prophylaxis may be considered in selected surgical populations.For example:Major surgery

ASH suggests extended prophylaxis over short-term prophylaxis in selected major surgical patients. Extended prophylaxis was generally defined as beyond approximately 3 weeks, compared with short-term prophylaxis up to about 2 weeks. 

This is not the same as routinely extending prophylaxis in every ICU medical patient.

Should every patient undergo screening Doppler?

No.Routine daily/weekly compression ultrasonography screening of asymptomatic ICU patients is not routinely recommended.

European guidance recommends against routine compression-DUS screening of critically ill patients. 

Perform diagnostic ultrasound when there is clinical suspicion:

• unilateral swelling
• new asymmetry
• unexplained hypoxemia
• unexplained tachycardia
• unexplained hemodynamic deterioration
• new PE suspicion

Anti-Xa monitoring

Anti-Xa level indicator of heparin efficacy  But APTT levels indicator of bleeding risk

Routine anti-Xa monitoring is not required for every patient receiving prophylactic LMWH.

Indication

• GFR 20-30 ml/min.
• Morbid obesity
• very low body weight <45 kg (♀),<57 kg (♂)
• pregnancy
• Draw a peak anti-Xa level ~4 hours after the 3rd dose 
• BID enoxaparin prophylaxis Peak anti-Xa = 0.2–0.4 IU/mL

Neurosurgical patients

Intracranial hemorrhage Initially: Mechanical prophylaxis

But Once:

• hematoma is stable
• repeat imaging demonstrates stability
• neurosurgical team agrees
• bleeding risk is acceptable

→ pharmacological prophylaxis can be initiated.

The consensus suggests considering chemical prophylaxis after approximately 24–48 h in hemorrhagic stroke/neurosurgical patients following clinical, radiological and neurosurgical assessment. The exact timing must be individualized.

Ischemic stroke

Immobility after ischemic stroke produces significant VTE risk.

In patients with low bleeding risk, pharmacological prophylaxis can be initiated relatively early.

The consensus suggests chemical prophylaxis within approximately 24 hours in ischemic stroke when bleeding risk is low. 

But remember:

Acute stroke thrombolysis/EVT patients

Timing must account for:

• thrombolytic therapy
• infarct size
• hemorrhagic transformation
• post-procedure imaging
• intracranial bleeding risk

Major trauma

Trauma is a special population because:

VTE risk ↑↑ but bleeding risk ↑↑

Initially, if active bleeding/high bleeding risk:

IPC/mechanical prophylaxis

Once:

• hemorrhage is controlled
• hemodynamics are stable
• intracranial lesion is stable where applicable
• no urgent operation is anticipated

→ start pharmacological prophylaxis.

The ISCCM consensus suggests considering chemical prophylaxis approximately 24–48 hours after severe trauma once bleeding/hematoma expansion risk is judged acceptable. 

Cancer patients

Cancer increases:VTE risk,recurrence risk

but also potentially:

• thrombocytopenia
• bleeding
• invasive procedures

Hospitalized patients with active cancer and acute medical illness generally receive pharmacological prophylaxis when bleeding risk is acceptable.

Pregnancy

Pregnancy is a hypercoagulable state.

Low bleeding risk→ LMWH or UFH

High bleeding risk→ mechanical prophylaxis

Liver disease

Elevated INR does NOT automatically mean “auto-anticoagulated.”

Patients with cirrhosis can develop:DVT,PE,portal vein thrombosisdespite prolonged INR.

Therefore:

Do not withhold VTE prophylaxis solely because the INR is elevated in cirrhosis.

In ACLF, SCCM guidance suggests LMWH over pneumatic compression stockings for VTE prophylaxis in hospitalized patients, although evidence quality is low. 

Obesity

• >100 kg and/or BMI >30 

Obesity creates two problems:

1. Increased VTE risk
2. Potential underdosing with fixed prophylactic doses

Therefore, in severe obesity:

• standard fixed-dose prophylaxis may be inadequate
• some centers use higher doses
• weight-based regimens may be considered
• anti-Xa monitoring may be considered in selected patients

BMI ≥40 kg/m² or marked obesity: consider increased prophylactic dosing (commonly enoxaparin 40 mg SC q12h) according to institutional protocol; anti-Xa monitoring may be considered in extreme obesity.

Thrombocytopenia

The 50,000/µL threshold is a commonly used practical ICU cutoff, not an absolute universal biological threshold.The overall clinical context matters.

if patient is on Concurrent antiplatelet agents?

Do not routinely reduce prophylactic LMWH or UFH solely because the patient is taking aspirin or another antiplatelet drug.

Assess VTE risk + bleeding risk + indication for antiplatelet therapy.

if patient is on Concurrent Warfarin?

Warfarin itself is already providing systemic anticoagulation. Adding prophylactic-dose heparin creates additional bleeding risk without a routine prophylactic benefit.

Epidural/spinal catheter

• This requires strict adherence to regional-anesthesia anticoagulation timing recommendations By ASRA
• The combination of:neuraxial catheter + anticoagulation can produce catastrophic spinal/epidural hematoma.
• Therefore, prophylactic LMWH/UFH timing must be coordinated with:insertion,removal,restart of neuraxial catheters.

Patient is on  CRRT?

CRRT creates a particularly complex situation.

Do not automatically assume that anticoagulation used to keep the CRRT circuit patent provides adequate systemic VTE prophylaxis.

For example:

• regional citrate anticoagulation → primarily circuit anticoagulation
• systemic heparin → may provide systemic anticoagulant effect

HIT(heparin-induced thrombocytopenia)

• If the patient develops suspected heparin-induced thrombocytopenia:Stop ALL heparin
• HIT is a prothrombotic condition.
• Use a suitable non-heparin anticoagulant ,Bivalirudin and argatroban are direct thrombin inhibitors (DTIs) that can be used here

References

1. Lilly CM, Kelly WF, Irwin RS, Boyle WA III, editors. Irwin and Rippe’s Intensive Care Medicine. 9th ed. Philadelphia: Wolters Kluwer; 2023.
2. Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198-3225. doi:10.1182/bloodadvances.2018022954.